Advertisement

International Journal of Clinical Pharmacy

, Volume 35, Issue 5, pp 711–718 | Cite as

Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia

  • Eun Kyung Lee
  • Yu Jeung LeeEmail author
Research Article

Abstract

Background Dementia is a disorder that is characterized by a chronic, progressive loss of cognitive function. Anticholinergic agents that are often used with elderly patients may cause a decline in cognitive capacity; therefore, they must be used with caution. Objective We aimed to identify the prescription patterns for anticholinergic drugs in elderly outpatients with a documented diagnosis of dementia through a retrospective analysis of electronic medical records. In addition, the study aimed to identify factors influencing these prescription patterns. Setting The Kyung Hee University Hospital in Korea. Methods We studied outpatients aged ≥65 years registered with dementia between January 1, 2011 and December 31, 2011. We reviewed prescription histories, identified anticholinergic prescriptions during the study period using the anticholinergic risk scale (ARS), and examined prescription patterns in the subjects. After analysing the ARS scores for each drug and subject, we performed a statistical analysis of the factors affecting prescription patterns for anticholinergic medications in patients with ARS scores of ≥2. Main outcome measure Prescription data on anticholinergic agents. Results Of 773 elderly dementia patients, 362 patients (46.83 %) were prescribed at least one anticholinergic medication. Of the ARS 2-point anticholinergics, nortriptyline was prescribed most frequently. Among ARS 3-point anticholinergics, cyproheptadine was prescribed most frequently. An ARS score of ≥2 was given in 255 (32.98 %) patients. A multivariate logistic regression analysis of the factors associated with anticholinergic prescription patterns revealed that those patients with comorbid Parkinson’s disease received significantly fewer prescriptions (OR = 0.544; 95% CI 0.364–0.813) and those patients who were prescribed 6–10 or ≥11 medications were significantly more likely to receive anticholinergic prescriptions (OR = 3.410; 95 % CI 2.228–5.220 and OR = 4.688; 95 % CI 2.993–7.344, respectively). Conclusion Approximately 33% of the elderly dementia patients in this study were prescribed clinically significant medication regimens totaling an ARS score of ≥2. Our findings show that the total number of medications and comorbid Parkinson’s disease both influence prescription patterns for anticholinergic medications.

Keywords

Anticholinergic agents Dementia Elderly Side effects South Korea 

Notes

Funding

None.

Conflicts of interest

None.

References

  1. 1.
    Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer’s disease: beyond cholinesterase inhibitors. Pharmacol Ther. 2012;134:8–25.PubMedCrossRefGoogle Scholar
  2. 2.
    Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD005593.Google Scholar
  3. 3.
    Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease : a meta-analysis. JAMA. 2003;289:210–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess. 2006;10:1–160.Google Scholar
  6. 6.
    Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Schneider LS. AD2000: donepezil in Alzheimer’s disease. Lancet. 2004;363:2100–1.PubMedCrossRefGoogle Scholar
  8. 8.
    American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616–31.CrossRefGoogle Scholar
  9. 9.
    Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc. 2007;55:S373–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33.PubMedGoogle Scholar
  12. 12.
    Boustani MA, Campbell NL, Munger S, Maidment I, Fox GC. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311–20.CrossRefGoogle Scholar
  13. 13.
    Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Bhattacharya R, Chatterjee S, Carnahan RM, Aparasu RR. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia. Am J Geriatr Pharmacother. 2011;9:434–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Chatterjee S, Mehta S, Sherer JT, Aparasu RR. Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey. Drugs Aging. 2010;27:987–97.PubMedCrossRefGoogle Scholar
  17. 17.
    Low LF, Anstey KJ, Sachdev P. Use of medications with anticholinergic properties and cognitive function in a young-old community sample. Int J Geriatr Psychiatry. 2009;24:578–84.PubMedCrossRefGoogle Scholar
  18. 18.
    Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60:198–203.PubMedCrossRefGoogle Scholar
  19. 19.
    Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am J Geriatr Psychiatry. 2005;13:535–8.PubMedGoogle Scholar
  20. 20.
    Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-Re′glat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol. 2005;59:143–51.PubMedCrossRefGoogle Scholar
  21. 21.
    Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc. 2002;50:836–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161:1099–105.PubMedCrossRefGoogle Scholar
  23. 23.
    Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale: results from the REPOSI study. Drugs Aging. 2013;30:103–12.PubMedCrossRefGoogle Scholar
  25. 25.
    Karimi S, Dharia SP, Flora DS, Slattum PW. Anticholinergic burden: clinical implications for seniors and strategies for clinicians. Consult Pharm. 2012;27:564–82.PubMedCrossRefGoogle Scholar
  26. 26.
    Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivelä SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol. 2002;55:809–17.PubMedCrossRefGoogle Scholar
  27. 27.
    Lau DT, Kasper JD, Potter DE, Lyles A. Potentially inappropriate medication prescriptions among elderly nursing home residents: their scope and associated resident and facility characteristics. Health Serv Res. 2004;39:1257–76.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Department of Clinical Pharmacy, College of PharmacyKangwon National UniversityChuncheon-siKorea
  2. 2.Department of Pharmacy, Kyung Hee University HospitalSeoulKorea

Personalised recommendations